| Title: |
Response to heart failure treatment in patients with anthracyclines and trastuzumab induced left ventricular dysfunction |
| Authors: |
Del Castillo, S; Fileni, L; Llamedo, C; Capdeville, S; Scarponi, C; Belziti, C; Falconi, M; Perez De Arenaza, D; Rossi, E; Pizarro, R |
| Source: |
European Heart Journal ; volume 43, issue Supplement_2 ; ISSN 0195-668X 1522-9645 |
| Publisher Information: |
Oxford University Press (OUP) |
| Publication Year: |
2022 |
| Description: |
Background Chemotherapy treatments with anthracyclines and Trastuzumab are widely used in different hematologic or solid malignancies but myocardial injury and left ventricular dysfunction, usually called cardiotoxicity (CTX), is a frequent adverse effect. Some studies have demonstrated that early detection and treatment of CTX is essential for the recovery of left ventricular ejection fraction (LVEF), however its behavior after starting treatment is not well established. Purpose Evaluate the behavior of LVEF after starting treatment for heart failure in patients with diagnosis of CTX. Methods Patients with diagnosis of solid or hematologic malignancies scheduled to receive therapy including anthracyclines and/or trastuzumab were prospectively included. Echocardiogram was performed before starting treatment, and then 3 and 6 months after. CTX was defined, according to guidelines, as a drop of LVEF ≥10% to a value |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1093/eurheartj/ehac544.799 |
| Availability: |
https://doi.org/10.1093/eurheartj/ehac544.799; https://academic.oup.com/eurheartj/article-pdf/43/Supplement_2/ehac544.799/46363095/ehac544.799.pdf |
| Rights: |
https://academic.oup.com/pages/standard-publication-reuse-rights |
| Accession Number: |
edsbas.3F77EE12 |
| Database: |
BASE |